Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
30.32
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
30.32
Bid (Size)
15.00 (1)
Ask (Size)
48.51 (2)
Prev. Close
30.32
Today's Range
30.32 - 30.32
52wk Range
13.36 - 30.67
Shares Outstanding
27,433,359
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Analyst Landscape: 7 Takes On AnaptysBio
May 10, 2024
Via
Benzinga
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+39.72%
+39.72%
1 Month
+28.20%
+28.20%
3 Month
+22.60%
+22.60%
6 Month
+31.71%
+31.71%
1 Year
+47.69%
+47.69%
More News
Read More
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Unveiling 4 Analyst Insights On AnaptysBio
April 01, 2024
Via
Benzinga
BTIG Research Predicts Over 118% Rally for These 3 Stocks
April 15, 2024
Via
InvestorPlace
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
April 12, 2024
Via
The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Via
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
April 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
March 12, 2024
Via
Benzinga
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
February 29, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
January 31, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Named a BioSpace 2024 Best Places to Work Winner
November 07, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Participation in November Investor Conferences
November 01, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
October 11, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
October 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 09, 2023
Via
Benzinga
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
October 09, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
October 09, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Via
MarketBeat
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
September 18, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.